The gut microbiota is comprised of tremendous organisms that living in the human gut, including bacteria, archaea, viruses, and fungi, which play key contribute to host metabolism and are considered potential sources of novel therapeutics. Several diseases are now thought to be influenced by processes in the gut microbiome. Those include cancer, autoimmune disorders such as multiple sclerosis and autism spectrum disorder. The gut microbiome also strongly interacts with certain drugs, including some mental-health therapeutics, and influences their effects.
• Explore the differences in Intestinal flora composition and content between the healthy state and in a variety of disease states
• Explore the differences in Intestinal flora composition and content during the development of a certain disease to search for disease-related biomarkers
• Explore the differences in Intestinal flora composition and content at different drug or diet intervention stages
• Explore the differences in Intestinal flora composition and content at different developmental stages of the same individual
• Explore the differences in Intestinal flora composition and content at different body parts of the same individual
With our next-generation sequencing (NGS) technology, PacBio SMRT sequencing, and Nanopore sequencing platforms, we have the tool to identify, quantify and analysis the gut microbiota. With this high-throughput technology we can perform complete metagenomics studies capable of surveying the genomes of entire communities, including those of unculturable organisms.
|Illumina Hiseq||Illumina Miseq||Ion PGM||PacBio SMRT system|
|Nanopore system||PCR-DGGE||Real-time qPCR||Clone library|
Creative Biogene offers complete solution for unbiased microbiome profiling includes not only consultancy, study design, sampling solutions and sequencing, but also downstream bioinformatic and biostatistical analyses.
Fig.1 High-throughput sequencing analysis process
Fig.2 PCR-DGGE analysis process
|Genomic DNA samples requirements |
• Quality requirements: ≥ 300 ng, ≥ 10 ng/μL, OD260/280=1.8-2.0, non-degradative
|Intestinal segment or feces samples requirements |
• Quality requirements: ≥1g
|Detectable Microorganisms |
|Basic analysis |
• Sequence Filtering and Trimming
|Routine analysis |
|Advanced data analysis |
• Phylogenetic Tree
1. Fuhrman JA. 2009. Microbial community structure and its functional implications. Nature 459:193–199.
2. Zhou, J. , He, Z. , Yang, Y. , Deng, Y. , & Alvarez-Cohen, L. . (2015). High-throughput metagenomic technologies for complex microbial community analysis: open and closed formats. mBio, 6(1).
3. Blandino, G., Inturri, R., Lazzara, F., Rosa, M.D., & Malaguarnera, L. (2016). Impact of gut microbiota on diabetes mellitus. Diabetes & metabolism, 42 5, 303-315.